Search

Your search keyword '"C. van Ruitenbeek"' showing total 2 results
Start Over Author "C. van Ruitenbeek"
2 results on '"C. van Ruitenbeek"'

1. The association between viral load and concurrent human papillomavirus infection at the genital and anal sites of young women and the impact of vaccination

Author

Kahren van Eer, Ihsane Laâbi, Birgit H.B. van Benthem, Renske D.M. Steenbergen, Audrey J. King, D. Adema, R. Buist-Arkema, A. Beerens, D. Luijt, S. Meijer, J. Schirm, M. Peeters, J. Rossen, H. Verbakel, P. van Esch, J. Verweij, A. van der Eijk, R. Huisman, C. Kerkhof, H. Korff, M. Schutten, J. Velzing, F. Verduyn-Lunel, S. Lakbiach, P. van Rosmalen, R. Schuurman, E. Doorn, L. Masthoff, E. Pannekoek, V. Sigurdsson, D. Abma, K. Adams, S. Bruisten, I. Linde, P. Oostvogel, C. Touwen, W. Vermeulen, A. Brink, J. Nelissen, P. Wolffs, N. Duijvendijk, P. Schneeberger, M. Dinnissen van Poppel, W. Melchers, Y. Poort, M.Hooghiemstra Izore, H. Huisman, J. Weel, F. Bosma, F. Geeraedts, I. Polman, P.van Goor Isala, M. Wolfhagen, C. de Mooij, E. van Koolwijk, M. Peters, C. Swanink, R. Tiemessen, T. van Zwet, J. Janssen, M. Pelsers, W. de Waal, G. Aalfs, J. Kiewiet, P. Sanders, H. van Buel- Bruins, C. van Bokhoven-Rombouts, P. Cornelissen, M. Kersten, C. van Ruitenbeek, I. Molenaar, M. Bugter, H. Götz, M. Illidge-Onder de Linden, M. Mattijssen, J. Stam, E. Swaders, F. de Groot, F. Postma, E. Brouwers, A. Niekamp, M. Smit, A. Botraby, D. Bukasa, C. de Haan, P. Hut-van Vliet, T. Taconis, M. de Graas, I. Hondelink, C. Kampman, A. Gelissen-Hansen, I. de Koning, H. van Kruchten, M. van de Pas, H. Fennema, T. Heijman, A. Hogewoning, A. van Leeuwen, M. van Rooijen, F. Neienhuijsen, and M. Pelgrim

Subjects
Human papillomavirus, Concurrent, Viral load, Vaccination, Genital, Anal, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Concurrent genital-anal human papillomavirus (HPV) infections may impose an increased anal cancer risk in women with HPV-related genital lesions. High viral load may facilitate genital-anal HPV concurrence. Genital and anal HPV is reduced by a bivalent HPV16/18 vaccine, yet the effect on concurrent genital-anal HPV remains unclear.This study analyzed viral load in concurrent genital-anal HPV infections, relative to genital-only and anal-only HPV infections and the impact of vaccination in young women. We included 1074 women, who provided both genital and anal swabs. HPV detection and genotyping was performed using the SPF10-DEIA-LiPA25. HPV copy numbers were measured with type-specific qPCRs and corrected for cellular content to obtain the viral load.Concurrent genital-anal HPV often had significantly higher genital viral load (0.09–371 c/cell) than genital-only HPV (3.17E-04-15.9 c/cell, p

Published
2022
Full Text
View/download PDF

2. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors

Author

J. Weel, P. Oostvogel, I. Molenaar, Audrey J. King, J. Schirm, E. Doorn, Petra F. G. Wolffs, Christian J. P. A. Hoebe, M. van de Pas, I. de Koning, J. Janssen, A. Gelissen-Hansen, M. Illidge-Onder de Linden, P. Sanders, M. Hooghiemstra, J. Kiewiet, Han S. A. Fennema, C. de Mooij, P. Hut-van Vliet, S. Lakbiach, Dirk S. Luijt, M. Pelsers, F. De Groot, T. van Zwet, M. Wolfhagen, H. Huisman, C. van Ruitenbeek, L. Masthoff, C. Touwen, H. Verbakel, Antoinette A. T. P. Brink, M. Schutten, K. Adams, I. Hondelink, N. Duijvendijk, R. Tiemessen, A.G.M. Buiting, Arjan Hogewoning, Robine Donken, Antoine M Beerens, T. de Haas, F. Postma, M. de Graas, F. Verduyn-Lunel, Jaco J. Verweij, Peter M. Schneeberger, T. Taconis, Titia Heijman, V. Sigurdsson, D. Adema, Elfi E. H. G. Brouwers, Petra J. Woestenberg, Menke J. de Smit, Johannes A. Bogaards, E. Pannekoek, E. van Koolwijk, I. Linde, P. Cornelissen, W. Vermeulen, C. van Bokhoven-Rombouts, Sylvia M. Bruisten, A. van Leeuwen, W. de Waal, R. Huisman, Marianne A B van der Sande, G. Aalfs, A. Botraby, Marcel Peeters, Hannelore M Götz, D. Abma, A.A. van der Eijk, R. Buist-Arkema, H. Korff, H. Bosch, C. de Haan, M. van Rooijen, H. van Buel-Bruins, S. Meijer, P. van Goor, E. Swaders, Fiona R. M. van der Klis, P. van Esch, M. Mattijssen, I. Polman, Birgit H B van Benthem, M. Dinnissen-van Poppel, J. Stam, John W. A. Rossen, Caroline M. A. Swanink, Rob Schuurman, T. Smits, J. Nelissen, C. Kampman, M. Peters, Willem J. G. Melchers, M. Pelgrim, C. Kerkhof, J. Velzing, Suzan Leussink, H. van Kruchten, D. Bukasa, P. van Rosmalen, Y. Poort, F. Neienhuijsen, M. Kersten, Anne-Marie Niekamp, R. Kleinspenkelink, CCA - Cancer biology and immunology, AII - Infectious diseases, Pathology, APH - Methodology, Other departments, APH - Global Health, Medical Microbiology and Infection Prevention, Neurology, Promovendi PHPC, Med Microbiol, Infect Dis & Infect Prev, and RS: CAPHRI - R4 - Health Inequities and Societal Participation

Subjects
0301 basic medicine, Cross-sectional study, Cross Protection, NETHERLANDS, Uterine Cervical Neoplasms, PAPILLOMAVIRUS, Ambulatory Care Facilities, Genital warts, GENITAL WARTS, 0302 clinical medicine, Prevalence, 030212 general & internal medicine, Cervical cancer, Human papillomavirus 16, Human papillomavirus 18, Human papillomavirus 11, Prevention & control, Vaccination, WOMEN, virus diseases, medicine.anatomical_structure, Infectious Diseases, ANOGENITAL WARTS, Vagina, Female, Warts, Adult, Microbiology (medical), medicine.medical_specialty, CERVICAL-CANCER, Adolescent, 030106 microbiology, Sexually Transmitted Diseases, Human papillomavirus vaccine, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Journal Article, Humans, Sex organ, Papillomavirus Vaccines, Human papillomavirus vaccine, L1 type 16, 18, Gynecology, Condylomata acuminata, business.industry, RISK HPV TYPES, Papillomavirus Infections, Vaccine trial, AS04-ADJUVANTED VACCINE, medicine.disease, Human papillomavirus 6, EFFICACY, Confidence interval, United Kingdom, Cross-Sectional Studies, INTRAEPITHELIAL NEOPLASIA, L1 type 16, business
Abstract

Objectives: Data from a vaccine trial and from post-vaccine surveillance in the United Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection against HPV-6/11 and protection against anogenital warts (AGW). We studied the effect of the bivalent vaccine on genital HPV-6/11 positivity and AGW in the Netherlands.Methods: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic attendants. Vaginal self-swabs were analyzed for type specific HPV and AGW were diagnosed at the STI-clinic. Prevalence of HPV-6 and/or HPV-11 and AGW were compared between self-reported vaccinated and unvaccinated women by log-binomial regression analysis, adjusted for demographics and risk behavior.Results: Of the 1198 women included, 56% reported to be vaccinated at least once. Relative to unvaccinated women, the adjusted prevalence ratio (PR) for HPV-6/11 was 1.03 (95% confidence interval [CI] 0.74-1.43) for women vaccinated at least once. The crude PR for AGW was 0.67 (95% CI 0.22-2.07) for women vaccinated at least once. Adjustment did not change these results.Conclusions: We observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW. (C) 2017 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results